Addictions, Drug & Alcohol Institute
Addictions, Drug & Alcohol Institute > ADAI Publications

ADAI Publications

31 publications found

  1. Carlini BH, Williams JR, Garrett SB, Hammond D. People with psychotic disorders are the most vulnerable to cannabis adverse health outcomes: A study in WA State, USA. Community Mental Health Journal 2026;62:889-895. [doi: 10.1007/s10597-025-01579-1]
  2. Carlini BH, Kellum LB, Garrett SB, Williams JR. Cannabis-related problems, adverse events, clinical experiences and barriers to intervening: Perspectives of health care providers in Washington State. Substance Use & Addiction Journal 2026;47(3):852-863. [doi: 10.1177/29767342261426116] PMID: 41910114
  3. Kellum LB, Carlini BH, Garrett S. Assessing Engagement in Cannabis Policy: A Survey of Washington State Elected Officials. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, May 2025
  4. Garrett SB, Williams J, Carlini BH, Hammond D. Cannabis consumer patterns, adverse events, and cannabis risk beliefs: A latent profile analysis in WA State. Drug and Alcohol Dependence 2025;273:112728. [doi: 10.1016/j.drugalcdep.2025.112728]
  5. Carlini BH, Kellum LB, Garrett SB, Nims LN. Threaten, distract, and discredit: Cannabis industry rhetoric to defeat regulation of high-THC cannabis products in Washington State, USA. Journal of Studies on Alcohol and Drugs 2024;85(3):322-329. [doi: 10.15288/jsad.23-00277] PMID: 38270913 PMCID: PMC11218453
  6. Carlini BH, Garrett SB, Matos P, Nims LN, Kestens Y. Identifying policy options to regulate high potency cannabis: A multiple stakeholder concept mapping study in Washington State, USA. International Journal of Drug Policy 2024;123:104270. [doi: 10.1016/j.drugpo.2023.104270] PMID: 38043404
  7. Carlini B, Garrett S, Kellum L, Nims L. Cannabis Research Report, 2021-2023. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, August 2023
  8. Carlini BH, Garrett S, Firth C, Pinksy I. Cannabis industry marketing violations in Washington State, 2014-2019. Journal of Studies on Alcohol and Drugs 2022;83:18-26. [doi: 10.15288/jsad.2022.83.18] PMID: 35040756
  9. Carlini BH, Garrett SB, Nims LN. The kids are not all right: E-cigarettes, cannabis co-use, and an emerging public health crisis: A commentary on Roberts et al. (2022). Journal of Studies on Alcohol and Drugs 2022;83(5):771-772. [doi: 10.15288/jsad.22-00167] PMID: 36136449
  10. Carlini BH, Garrett SB, Firth C, Harwick R. Cannabis retail staff (“budtenders”) attitudes towards cannabis effect on health and experiences interacting with consumers – Washington State USA. Journal of Psychoactive Drugs 2022;29:1-9. [doi: 10.1080/02791072.2021.1900628] PMID: 33781175
  11. Carlini BH, Harwick R, Garrett S. Anytime is the right time: A content analysis of marijuana ads in freely distributed print media in western Washington State, USA. Substance Use & Misuse 2020;55:806-817. [doi: 10.1080/10826084.2019.1703749] PMID: 31876238
  12. Harwick R, Carlini BH, Garrett SB. A taxonomy of consumers’ perspectives on the function of cannabis in their lives: A qualitative study in WA State, USA. Journal of Psychoactive Drugs 2020;52(5):393-400. [doi: 10.1080/02791072.2020.1763522] PMID: 32501752
  13. Carlini BH, Garrett SB. Drug helplines and adult marijuana users: an assessment in Washington, Colorado, Oregon, and Alaska. Substance Abuse 2018;39(1):3-5. [doi: 10.1080/08897077.2017.1355872] PMID: 28715253
  14. Garrett SB, Doyle SR, Peavy MK, Wells EA, Owens MD, Shores-Wilson K, DiCenzo J, Donovan DM. Age differences in outcomes among patients in the “Stimulant Abuser Groups to Engage in 12-Step” (STAGE-12) intervention. Journal of Substance Abuse Treatment 2018;84:21-29. [doi: 10.1016/j.jsat.2017.10.012] PMID: 29195590 PMCID: PMC5726800
  15. Carlini BH, Garrett SB, Harwick RM. Beyond joints and brownies: Marijuana concentrates in the legal landscape of WA State, USA. International Journal of Drug Policy 2017;42:26-28. [doi: 10.1016/j.drugpo.2017.01.004] PMID: 28171805
  16. Peavy KM, Garrett S, Doyle SR, Donovan DM. A comparison of African American and Caucasian stimulant users in 12-step facilitation treatment. Journal of Ethnicity in Substance Abuse 2017;16(3):380-399. [doi: 10.1080/15332640.2016.1185657] PMID: 27294812 PMCID: PMC5368022
  17. Carlini BH, Garrett SB, Carter GT. Medicinal cannabis: A survey among health care providers in Washington State. American Journal of Hospice and Palliative Medicine 2017;34(1):85-91. [doi: 10.1177/1049909115604669] PMID: 26377551
  18. Hartzler B, Garrett SB. Interest and preferences for contingency management design among addiction treatment clientele. American Journal of Drug and Alcohol Abuse 2016;42(3), 287-295. [doi: 10.3109/00952990.2015.1096365] PMID: 26646619 PMCID: PMC4877230
  19. Hatch-Maillette MA, Wells EA, Doyle SR, Brigham GS, Daley D, DiCenzo J, Donovan DM, Garrett SB, Horigian VE, Jenkins L, Killeen T, Owens MD, Perl HI. Predictors of 12-step attendance and participation for individuals with stimulant use disorders. Journal of Substance Abuse Treatment 2016;68:74-82. [doi: 10.1016/j.jsat.2016.06.007] PMID: 27431050 PMCID: PMC5462490
  20. Wells EA, Donovan DM, Daley DC, Doyle SR, Brigham G, Garrett SB, Ingalsbe MH, Hatch-Maillette MA, Perl HI, Walker R. Is level of exposure to a 12-step facilitation therapy associated with treatment outcome? Journal of Substance Abuse Treatment 2014;47(4):265-74. [doi: 10.1016/j.jsat.2014.06.003] PMID: 25064421 PMCID: PMC4138275